Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q3 2024

Q3 2024 biggest moves
  • GILDGILD

    Gilead Sciences

    Sold out

    was 1.7% of portfolio

  • NBIXNBIX

    Neurocrine Biosciences

    Added 91%

    now 2.3% of portfolio

  • SGRYSGRY

    Surgery Partners

    Cut 62%

    now 0.9% of portfolio

  • INDVINDV

    INDIVIOR

    New

    0.7% of portfolio

644 changes in all

Top Holdings443 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$2B30.6%——
13 qtrssince 2021-Q3
Unchanged
0
VTRS

Viatris Inc.

24M$278.6M4.2%$11.16-4.15%
16 qtrssince 2020-Q4
Increased
63
CNC

Centene Corporation

2.7M$199.7M3.0%$67.97+10.75%
20 qtrssince 2019-Q4
Increased
52
MRUS
MRUSDelisted

MERUS N V

3.4M$170.3M2.5%——
12 qtrssince 2021-Q4
Increased
64
OSCR

Oscar Health, Inc.

7.9M$166.5M2.5%$10.52+101.62%
4 qtrssince 2023-Q4
Increased
59
174.4M$165.8M2.5%——
3 qtrssince 2024-Q1
Unchanged
0
SPRY

ARS Pharmaceuticals, Inc.

11.1M$160.6M2.4%$8.53+69.99%
8 qtrssince 2022-Q4
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.3M$151.7M2.3%$105.09+9.64%
15 qtrssince 2021-Q1
Increased
82
LRMR

Larimar Therapeutics, Inc.

21.2M$139.1M2.1%$6.64-1.34%
18 qtrssince 2020-Q2
Unchanged
0
WAY

Waystar Holding Corp.

5M$138.1M2.1%——
2 qtrssince 2024-Q2
Unchanged
0
RVMD

Revolution Medicines, Inc.

2.9M$132.1M2.0%$26.00+74.44%
19 qtrssince 2020-Q1
Decreased
0
ALHC

Alignment Healthcare, Inc.

10.9M$128.3M1.9%$6.20+90.76%
6 qtrssince 2023-Q2
Decreased
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

6.2M$123.8M1.9%——
9 qtrssince 2022-Q3
Decreased
0
??
ACCOLADE INCDelisted
Bond
132.6M$122M1.8%——
10 qtrssince 2022-Q2
Unchanged
0
100M$117.1M1.7%——
1 qtr
New
69
AHCO

AdaptHealth Corp.

9.7M$109.1M1.6%$18.05-37.77%
20 qtrssince 2019-Q4
Decreased
0
BKD

Brookdale Senior Living Inc.

15.6M$106M1.6%$4.41+53.95%
20 qtrssince 2019-Q4
Unchanged
0
KURA

Kura Oncology, Inc.

5.4M$105.7M1.6%$14.13-38.36%
14 qtrssince 2021-Q2
Unchanged
0
??
ALPHATEC HLDGS INCDelisted
Bond
117.5M$105.7M1.6%——
1 qtr
New
68
70M$103M1.5%——
2 qtrssince 2024-Q2
Unchanged
0
$6.7B
AUM
443
Positions
Q3 2024
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2023-Q2$4,684,196,2414.42578396262%
2023-Q3$4,538,793,245-3.10411836992%
2023-Q4$5,415,638,75919.3189129063%
2024-Q1$5,748,069,8946.13835504533%
2024-Q2$6,010,510,6294.56571927342%
2024-Q3$6,692,805,83111.3517011135%
Activity profile
$ moved · Q3'24
New29%Increased18%Decreased16%Exited37%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.0 quarters
<1Q45%1-4Q37%1-2Y4%2Y+15%

Deerfield Management Company, L.P. manages $6.7B across 443 positions as of Q3 2024. Top holdings: NUVL (30.6%), VTRS (4.2%), CNC (3.0%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$7B
NUVL30.56%
VTRS4.16%
CNC2.98%
MRUS2.54%
OSCR2.49%
INTEGRA LIFE2.48%
SPRY2.40%
NBIX2.27%
LRMR2.08%
WAY2.06%
Other1.97%

Portfolio allocation by GICS sector

Sectors11
Healthcare96.74%
Technology0.61%
Industrials0.57%
Unknown0.50%
Financial Services0.45%
Consumer Cyclical0.35%
Consumer Defensive0.33%
Real Estate0.16%
Basic Materials0.10%
Utilities0.07%
Other0.12%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used